Tag Archives: acute coronary syndrome

SEMPER-FI: el resurgimiento del balón de contrapulsación

EuroPCR 2018 | SEMPER-FI: The Reemergence of the Intra-Aortic Balloon Counterpulsation

EuroPCR 2018 | SEMPER-FI: The Reemergence of the Intra-Aortic Balloon Counterpulsation

The intra-aortic balloon counterpulsation affects patients through a combination of coronary flow improvement and afterload reduction. It has been the subject matter of several studies, but its benefit as mechanical support has not been proven. This work aims to prove the benefits of balloon counterpulsation in patients with ST-segment elevation acute myocardial infarction who, after

Registro Sueco con stent SYNERGY: por primera vez stent probado en angioplastia primaria

EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time

The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,

TAVI-compressor

Elderly Patients with ACS: Clopidogrel or Reduced-Dose Prasugrel?

Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome (ACS), and display higher platelet reactivity under clopidogrel when compared to younger patients. A 5-mg dose of prasugrel would provide more predictable platelet inhibition than clopidogrel in elderly populations, without the risk of bleeding entailed by the full

ACC 2018 | SECURE-PCI: Altas dosis de estatinas previo a la angioplastia podrían ayudar

ACC 2018 | SECURE-PCI: High Dose of Statins pior PCI Could Help

Patients undergoing acute coronary syndrome (ACS) loaded with a high dose of statins prior diagnostic catheterization do not seem to benefit from this strategy. However, when looking at those undergoing PCI alone (excluding all patients who had received surgery or medical treatment), the benefit appears as a reduction of combined major events. The benefit of atorvastatin loading

ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS

This study compared 6 vs 12 or more months of dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) receiving contemporary DES, and it did not find differences in combined endpoint. However, looking at primary endpoint components separately, there were more infarctions in patients with a short DAPT scheme that we cannot ignore. Prolonging antiaggregation

Sorpresivo pronóstico para los infartos con coronarias normales

Surprising Prognosis for Normal ACS

St elevation acute coronary syndromes are typically caused by thrombotic obstruction of a coronary artery due to ruptured atherosclerosis plaque. However, there is a significant number of patients with similar clinical presentations but no evidence of obstructive coronary artery disease (CAD). Read also: CTO in patients with acute myocardial infarction increases long term mortality. In general, patients without

Seguimiento con OCT de las erosiones de placa con tratamiento médico y sin stent

OCT Follow-Up of Plaque Erosion with Medical Therapy and Without Stenting

Most acute coronary syndromes (ACS) are caused by the following three different pathologies: Plaque rupture Plaque erosion Calcified nodule In daily clinical practice, all patients who experience them are treated with angioplasty, regardless of which of these physiopathologies led to the ACS in each case. Some early reports indicate that patients with plaque erosion might

Does a Combination of Diabetes and Acute Coronary Syndrome Change the Revascularization Strategy?

The results of the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial have shown a lower rate of events in patients with diabetes and stable multivessel disease who were randomized to undergo myocardial revascularization surgery, compared to those who underwent angioplasty. Surgery even showed a mortality reduction that

ticagrelor-clopidogrel-compressor

Clopidogrel or Ticagrelor in Patients with Acute Coronary Syndrome Treated with New-Generation DES: CHANGE DAPT

Courtesy of Dr. Pablo Baglioni. This is a prospective observational study with a 1-year follow-up analyzing 2062 patients with acute coronary syndrome (ACS) who have been treated with coronary angioplasty using new-generation drug-eluting stents (DES). Patients were included between December 21, 2012 and August 25, 2015. On May, 2014, due to changes in international guidelines, clopidogrel

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Early Coronary Angiography in High-Risk Non-ST-Elevation ACS

Coronary angiography is essential for patients admitted with non-ST-elevation acute coronary syndrome, since it allows physicians to confirm the diagnosis, stratify the risk, and define the revascularization and antithrombotic management strategies.   There is no doubt that these patients should be studied invasively, but the timing for that is still uncertain.   Coronary catheterization within

Top